EGFR Overexpression

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Brain Glioblastoma1
EGFR Overexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID474 In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival. PMID 14583498 · Shinojima et al., 2003 · Open in CIViC	civic
Colorectal Adenocarcinoma3
EGFR Overexpression AND KRAS Mutation	Cetuximab	Predictive	B	Supports Adverse Response	3	submitted	EID11059 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Brain Glioblastoma1

EGFR Overexpression

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID474

In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival.

PMID 14583498 · Shinojima et al., 2003 · Open in CIViC

civic

Colorectal Adenocarcinoma3

EGFR Overexpression AND KRAS Mutation

Cetuximab

Predictive

Supports Adverse Response

submitted

EID11059

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

Esophageal Squamous Cell Carcinoma4
EGFR Overexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID784 55 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 ± 0.5 … (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC	civic
EGFR Overexpression	Unspecified therapy	Predictive	B	Does Not Support Sensitivity Response	3	rejected	EID833 Expression of EGFR in 55 samples of esophageal squamous cell carcinoma with IHC was not predictive of response to EGFR inhibitor nimotuzumab. EGFR overexpression was related to poor OS and PFS. PMID 26459251 · Jia et al., 2016 · Open in CIViC	civic
EGFR Overexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	3	rejected	EID834 Overexpression of EGFR in 55 samples of esophageal squamous cell carcinoma as assesesed by IHC, was related to poor OS and PFS (PFS: 5.8 ± 0.5 vs. 11.0 ± 2.8 months, P = 0.007; OS: 9.7 ± 0.5 vs. 21.5… (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC	civic
EGFR Overexpression	Nimotuzumab	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID783 55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to mod… (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC	civic

Esophageal Squamous Cell Carcinoma4

EGFR Overexpression

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID784

55 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 ± 0.5 … (full text at CIViC)

PMID 26459251 · Jia et al., 2016 · Open in CIViC

civic

EGFR Overexpression

Unspecified therapy

Predictive

Does Not Support Sensitivity Response

rejected

EID833

Expression of EGFR in 55 samples of esophageal squamous cell carcinoma with IHC was not predictive of response to EGFR inhibitor nimotuzumab. EGFR overexpression was related to poor OS and PFS.

PMID 26459251 · Jia et al., 2016 · Open in CIViC

civic

EGFR Overexpression

(prognostic)

Prognostic

Supports Poor Outcome

rejected

EID834

Overexpression of EGFR in 55 samples of esophageal squamous cell carcinoma as assesesed by IHC, was related to poor OS and PFS (PFS: 5.8 ± 0.5 vs. 11.0 ± 2.8 months, P = 0.007; OS: 9.7 ± 0.5 vs. 21.5… (full text at CIViC)

PMID 26459251 · Jia et al., 2016 · Open in CIViC

civic

EGFR Overexpression

Nimotuzumab

Predictive

Does Not Support Sensitivity Response

accepted

EID783

55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to mod… (full text at CIViC)

PMID 26459251 · Jia et al., 2016 · Open in CIViC

civic

Glioblastoma1
EGFR Overexpression	Bevacizumab + LomustineCombination	Predictive	B	Supports Sensitivity Response	4	submitted	EID10894 "Classical" glioblastoma patients (referred to as group IGS-18) exhibited overexpression of EGFR and showed improved survival with combination therapy of bevacizumab and lomustine with a median OS 11.… (full text at CIViC) PMID 26762204 · Erdem-Eraslan et al., 2016 · Open in CIViC	civic

Glioblastoma1

EGFR Overexpression

Bevacizumab + LomustineCombination

Predictive

Supports Sensitivity Response

submitted

EID10894

"Classical" glioblastoma patients (referred to as group IGS-18) exhibited overexpression of EGFR and showed improved survival with combination therapy of bevacizumab and lomustine with a median OS 11.… (full text at CIViC)

PMID 26762204 · Erdem-Eraslan et al., 2016 · Open in CIViC

civic

Glioma1
EGFR Overexpression	Gefitinib + Radiation TherapyCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID7803 Study of malignant glioma cells with EGFR amplification, IGRG88. IGRG88 cells showed a 946 fold increase of EGFR mRNA when compared to IGRG119, a tumor known to express low levels of EGFR mRNA. IHC … (full text at CIViC) PMID 18386816 · Geoerger et al., 2008 · Open in CIViC	civic

Glioma1

EGFR Overexpression

Gefitinib + Radiation TherapyCombination

Predictive

Supports Sensitivity Response

submitted

EID7803

Study of malignant glioma cells with EGFR amplification, IGRG88. IGRG88 cells showed a 946 fold increase of EGFR mRNA when compared to IGRG119, a tumor known to express low levels of EGFR mRNA. IHC … (full text at CIViC)

PMID 18386816 · Geoerger et al., 2008 · Open in CIViC

civic

Head and Neck Squamous Cell Carcinoma3
EGFR Overexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID782 Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC) PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC	civic
EGFR Overexpression	Cetuximab	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID692 EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcino… (full text at CIViC) PMID 23265711 · Licitra et al., 2013 · Open in CIViC	civic
EGFR Overexpression	Cetuximab + DocetaxelCombination	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID849 47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFR. EGFR expression had no imp… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC	civic

Head and Neck Squamous Cell Carcinoma3

EGFR Overexpression

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID782

Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC)

PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC

civic

EGFR Overexpression

Cetuximab

Predictive

Does Not Support Sensitivity Response

accepted

EID692

EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcino… (full text at CIViC)

PMID 23265711 · Licitra et al., 2013 · Open in CIViC

civic

EGFR Overexpression

Cetuximab + DocetaxelCombination

Predictive

Does Not Support Sensitivity Response

accepted

EID849

47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFR. EGFR expression had no imp… (full text at CIViC)

PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma5
EGFR Overexpression	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	B	Supports Sensitivity Response	4	accepted	EID693 EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone… (full text at CIViC) PMID 22056021 · Pirker et al., 2012 · Open in CIViC	civic
EGFR Overexpression	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	B	Supports Sensitivity Response	3	accepted	EID737 In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison … (full text at CIViC) PMID 26439803 · Park et al., 2015 · Open in CIViC	civic
EGFR Overexpression	Erlotinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID5827 A total of 57 patients with HER1/EGFR positive non-small cell lung cancer were treated with erlotinib therapy. Two patients achieved a complete response, five had a partial response, and 22/57 patient… (full text at CIViC) PMID 15310767 · Pérez-Soler et al., 2004 · Open in CIViC	civic
EGFR Overexpression	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3797 A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 del… (full text at CIViC) PMID 21969500 · Brugger et al., 2011 · Open in CIViC	civic
EGFR Overexpression	Gefitinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID954 82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients). Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas… (full text at CIViC) PMID 16707605 · Dziadziuszko et al., 2006 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma5

EGFR Overexpression

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Predictive

Supports Sensitivity Response

accepted

EID693

EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone… (full text at CIViC)

PMID 22056021 · Pirker et al., 2012 · Open in CIViC

civic

EGFR Overexpression

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Predictive

Supports Sensitivity Response

accepted

EID737

In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison … (full text at CIViC)

PMID 26439803 · Park et al., 2015 · Open in CIViC

civic

EGFR Overexpression

Erlotinib

Predictive

Supports Sensitivity Response

submitted

EID5827

A total of 57 patients with HER1/EGFR positive non-small cell lung cancer were treated with erlotinib therapy. Two patients achieved a complete response, five had a partial response, and 22/57 patient… (full text at CIViC)

PMID 15310767 · Pérez-Soler et al., 2004 · Open in CIViC

civic

EGFR Overexpression

Erlotinib

Predictive

Supports Sensitivity Response

—

submitted

EID3797

A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 del… (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC

civic

EGFR Overexpression

Gefitinib

Predictive

Supports Sensitivity Response

accepted

EID954

82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients). Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas… (full text at CIViC)

PMID 16707605 · Dziadziuszko et al., 2006 · Open in CIViC

civic

Evidence by cancer (18 items)

Clinical significance (0)